Inclusion Criteria:

          -  Histologically confirmed metastatic uveal melanoma in the liver; patients must have at
             least one measurable liver metastasis that is ≥ 10 mm in longest diameter by spiral
             computed tomography (CT) scan or magnetic resonance imaging (MRI); the total volume of
             the tumors must be less than 50% of the liver volume

          -  Willingness and ability to give informed consent

          -  Agreement to access archival tissue or agreement for tumor biopsy prior to treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1

          -  Serum creatinine ≤ 2.0 mg/dl

          -  Granulocyte count ≥ 1000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Bilirubin ≤ 2.0 mg/ml

          -  Albumin ≥ 3.0 g/dl

          -  Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x
             upper limit of normal (ULN)

          -  Alkaline phosphatase less than 1.5 times ULN (grade 1)

          -  Women must not be pregnant or breast-feeding

          -  Women of child-bearing potential must use at least two accepted and effective methods
             of contraception and/or to abstain from sexual intercourse for at least 4 months (120
             days) after the last dose of nivolumab and/or ipilimumab; sexually active males must
             also use at least two accepted and effective methods of contraception and/or to
             abstain from sexual intercourse for at least 4 months (120 days) after the last dose
             of nivolumab and/or ipilimumab

        Exclusion Criteria:

          -  Failure to meet any of the criteria set forth in the inclusion criteria section

          -  Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody

          -  Previous liver-directed treatments including chemoembolization, radiosphere, hepatic
             arterial perfusion, or drug-eluting beads

          -  Presence of symptomatic liver failure including ascites and hepatic encephalopathy

          -  Presence of untreated brain metastases; if patients have had previous treatment for
             the brain metastasis, an MRI or CT scan of the brain must confirm the stabilization of
             the brain metastasis for more than 2 months

          -  Occlusion of the main portal vein, or inadequate collateral flow around an occluded
             portal vein as determined by angiography

          -  Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial
             infarction within 6 months of entry

          -  Presence of any other medical complication that implies survival of less than six
             months

          -  Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding

          -  Significant allergic reaction to contrast dye or granulocyte-macrophage
             colony-stimulating (GM-CSF)

          -  Immunosuppressive treatments within 4 weeks prior to embolization, unless prednisone ≤
             5 mg or equivalent

          -  Pregnancy or breast-feeding women

          -  Patients with active hepatitis with serum glutamic-oxaloacetic transaminase (SGOT) and
             serum glutamate pyruvate transaminase (SGPT) equal or greater than 5 times normal

          -  Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy

          -  Significant arteriovenous shunt identified on angiography of the hepatic artery

          -  Positive for known human immunodeficiency virus (HIV) Infection

          -  Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary
             fibrosis

          -  Active infection

          -  Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis,
             but not including hypothyroidism or psoriasis if condition has been stable for 2
             months or greater